<DOC>
	<DOCNO>NCT00004489</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine bioavailability biologic effect alendronate bone metabolism patient cystic fibrosis . II . Assess safety efficacy treatment regimen improve osteoporosis patient population .</brief_summary>
	<brief_title>Randomized Study Alendronate Adult Patients With Cystic Fibrosis Related Osteoporosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind study . Patients stratify accord sex ( male v female ) osteoporosis disease severity ( mild v severe ) . Patients randomize one two treatment arm . Patients undergo bioavailability assessment confirm ability absorb alendronate . Arm I : Patients receive calcium vitamin D supplement placebo daily one month . Arm II : Patients receive calcium vitamin D supplement oral alendronate daily one month . Treatment continue difference see bone mineral density treatment arm . Patients follow biochemical response week 6 , 12 , 52 . Bone mineral density measure 1 year 2 year . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis cystic fibrosis Mild moderate lung disease At least one site specific ( spine femur ) bone mineral density represent low bone mass osteopenia ( great 1 standard deviation peak bone mass ) Prior/Concurrent Therapy Endocrine therapy : At least 3 month since prior corticosteroid Patient Characteristics Performance status : Ambulatory Renal : Creatinine great 3 mg/dL No renal failure Other : No history esophagitis No allergy alendronate Not pregnant Fertile female patient must use effective barrier contraception progestin oral contraceptive ( e.g. , norethindrone ) Ability comply treatment No intestinal problem cystic fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>rare disease</keyword>
</DOC>